Big Health Care Companies Are Undervalued
McKesson and Walgreens are strong, healthy companies, despite recent downturns in their stock prices, a CEO in the investment field says.
Botox Maker Allergan Sold to AbbVie for $63B
AbbVie faces pressure to diversify its portfolio as Humira, the world’s best-selling drug, faces increased competition from cheaper versions in Europe.
Proposals to Separate Joint CEO-Board Chair Roles Go Nowhere
Each year dozens of shareholder proposals seek to quash potential conflicts of interest by calling for an independent chair. But they hardly ever pass.
Biotech CFO Pitches Fundamentals, not Financials
Ironwood’s Tom Graney tries to focus investors on the firm’s pipeline rather than its revenue.
Allergan Buys CoolSculpting Company for $2.4B
The acquisition of Zeltiq Aesthetics' system for using cooling to eliminate fat cells gives Allergan access to the growing body-contouring market.
Allergan Fined $15M Over Disclosure Failures
The SEC says the drug maker failed to timely inform investors about its merger talks with Salix and Actavis.
Allergan Bets on Tobira’s Liver Disease Drug
The Botox maker will pay up to $1.7 billion for Tobira, the developer of an experimental treatment for a nonalcoholic fatty liver condition.
Pfizer Makes Cancer Play With Medivation Deal
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
Finance Roundup for Executives
Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.
Did Treasury Target Pfizer-Allergan Inversion?
The Obama Administration and the Allergan CEO disagree about whether the government wanted specifically to kill the giant drug merger.